Scarica l'app Stockscreener
22.02
0.68%
-0.15
Dopo l'orario di chiusura:
22.02
Precedente Chiudi:
$22.17
Aprire:
$22.25
Volume 24 ore:
567.25K
Relative Volume:
0.43
Capitalizzazione di mercato:
$2.81B
Reddito:
$24.05M
Utile/perdita netta:
$-243.33M
Rapporto P/E:
-7.339
EPS:
-3.0004
Flusso di cassa netto:
$-370.18M
1 W Prestazione:
-3.72%
1M Prestazione:
-14.95%
6M Prestazione:
+201.64%
1 anno Prestazione:
+354.96%
Intervallo 1D:
$21.73
$22.72
Intervallo di 1 settimana:
$20.53
$23.39
Portata 52W:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Nome
Alumis Inc
Settore
Industria
Telefono
650-231-6625
Indirizzo
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
22.02 | 2.83B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | Raymond James | Strong Buy |
| 2026-02-25 | Iniziato | Stifel | Buy |
| 2026-01-21 | Iniziato | Chardan Capital Markets | Buy |
| 2025-07-25 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Ripresa | Guggenheim | Buy |
| 2025-01-30 | Iniziato | Oppenheimer | Outperform |
| 2024-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Iniziato | Guggenheim | Buy |
| 2024-07-23 | Iniziato | Leerink Partners | Outperform |
| 2024-07-23 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Alumis Inc Borsa (ALMS) Ultime notizie
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors - simplywall.st
Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS - Benzinga
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model? - Yahoo Finance
Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40 - Moomoo
ALMS Maintained by Chardan Capital -- Price Target Raised to $40 - GuruFocus
Alumis price target raised to $40 from $38 at Chardan - TipRanks
Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating - marketscreener.com
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones - Sahm
This Alumis analyst is no longer bullish; here are top 5 downgrades for Friday - MSN
ALUMIS INC. ($ALMS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] ALUMIS INC. SEC Filing - Stock Titan
[DEF 14A] ALUMIS INC. Definitive Proxy Statement - Stock Titan
Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026 - IndexBox
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors? - Sahm
Alumis’ Envudeucitinib Hits 68% PASI 90 in Phase 3 Psoriasis Trial - The Clinical Trial Vanguard
HC Wainwright & Co. downgrades Alumis (ALMS) - MSN
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back - AOL.com
Morgan Stanley Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $39 - Moomoo
All News about Alumis Inc.Common Stock - The Chronicle-Journal
ALMS Maintained by Guggenheim -- Price Target Raised to $34 - GuruFocus
ALMS Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset - Endpoints News
Stifel reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Stifel reiterates Alumis stock rating on psoriasis trial data - Investing.com
Why Alumis Inc. Stock Is Sliding After Good News - TipRanks
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Alumis(ALMS.US) to Hold Rating, Maintains Target Price $25 - Moomoo
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $51 - Moomoo
Guggenheim raises Alumis stock price target to $34 on psoriasis data By Investing.com - Investing.com South Africa
Guggenheim raises Alumis stock price target to $34 on psoriasis data - Investing.com
Alumis Q1 Loss Narrows, Revenue Falls; Shares Down Pre-Bell - marketscreener.com
HC Wainwright Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects - Fierce Biotech
Alumis (ALMS) Reports Q1 Earnings with Focus on Psoriasis Treatm - GuruFocus
ALMS SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss - Yahoo Finance
ALMS Financials: Income Statement, Balance Sheet & Cash Flow | Alumis Inc - Stock Titan
Alumis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
[10-Q] ALUMIS INC. Quarterly Earnings Report - Stock Titan
Q1 2026 earnings and future milestones announced by ALUMIS INC. - Traders Union
Alumis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Envudeucitinib Phase 3 gains and Q1 2026 results for Alumis (NASDAQ: ALMS) - Stock Titan
Earnings Flash (ALMS) Alumis Inc. Reports Q1 Revenue $1.7M, vs. FactSet Est of $2.5M - marketscreener.com
Press Release: Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements - Moomoo
Alumis psoriasis pill hits 68% PASI 90 in Phase 3 trial - Stock Titan
ALUMIS INC. to present new biomarker data on investigational PsO treatment at Chicago conference - Traders Union
TradingKey - TradingKey
ALMS Stock Price, Quote & Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug - AOL.com
Alumis Inc Azioni (ALMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):